Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01960023 | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | NSABP Foundation IncNETWORK | 1 | Oct 27, 2021 | clinicaltrials |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01273402 | Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma(PANC-001) | withdrawn | Phase 1 | 0 | Roger Williams Medical CenterOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03380689 | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer(SIRB2) | withdrawn | Phase 1 | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 8, 2021 | clinicaltrials |
| NCT00578396 | Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention | withdrawn | Phase 1 | 0 | University of California, IrvineOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04205071 | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer | withdrawn | Phase 1 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Jan 19, 2021 | clinicaltrials |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jan 15, 2021 | clinicaltrials |
| NCT04195373 | A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract | withdrawn | Phase 1 | 0 | Themis Bioscience GmbHINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT01302613 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | withdrawn | Phase 1 | 0 | University of MinnesotaOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 0 | May 20, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | withdrawn | Phase 1 | 0 | Lynkcell Inc.OTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | withdrawn | Phase 1 | 0 | University of HawaiiOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 | 0 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Sep 25, 2019 | clinicaltrials |
| NCT02449967 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Piedmont Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT02581501 | Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | withdrawn | Phase 1 | 0 | Stamford HospitalOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT00968604 | C-VISA BikDD: Liposome in Advanced Pancreatic Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT02868632 | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | withdrawn | Phase 1 | 0 | NYU Langone HealthOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT00005030 | SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 14, 2018 | clinicaltrials |
| NCT03182894 | Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | James J LeeOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT03307603 | Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT02105350 | A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 0 | Feb 19, 2018 | clinicaltrials |
| NCT01956864 | Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | withdrawn | Phase 1 | 0 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02630420 | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 0 | Oct 26, 2017 | clinicaltrials |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Oct 6, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Oct 27, 2021source: clinicaltrials